Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0LHZWB
ADC Name
ASN-004
Synonyms
ASN004; ASN 004
   Click to Show/Hide
Organization
Asana BioSciences LLC
Drug Status
Phase 1
Indication
In total 6 Indication(s)
Colorectal cancer [ICD11:2B91]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
Lung cancer [ICD11:2C25]
Phase 1
Metastatic breast cancer [ICD11:2C6Y]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Drug-to-Antibody Ratio
10-12
Antibody Name
Anti-5T4 scFv-Fc Anti-ody
  Antibody Info 
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
Auristatin F hydroxypropylamide (AF-HPA)
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Dolaflexin ADC platform technology.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 17 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 28.2
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 54.3
%
Lung cancer cells
Lung cancer
Tumor Growth Inhibition value (TGI) 
≈ 55.5
%
Cervical advanced-stage cancer cells
Cervical advanced-stage cancer
Tumor Growth Inhibition value (TGI) 
≈ 94.2
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 96.3
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Gastric cancer cells
Gastric cancer
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Gastric cancer cells
Gastric cancer
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Lung cancer cells
Lung cancer
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Lung cancer cells
Lung cancer
Tumor Growth Inhibition value (TGI) 
≈ 100
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
A431 cells
Skin squamous cell carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 32 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.07
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.09
nM
MDA-MB-231 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.09
nM
SCaBER cells
Bladder squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.12
nM
5637 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.12
nM
A-375 cells
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
0.15
nM
MCF-7 cells
Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.17
nM
DU145 cells
Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.18
nM
HeLa cells
Endocervical adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.23
nM
MDA-MB-231 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.25
nM
A-549 cells
Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.26
nM
A431 cells
Skin squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.31
nM
SW780 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.34
nM
U-87MG cells
Glioblastoma
Half Maximal Inhibitory Concentration (IC50) 
0.42
nM
PC-3 cells
Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.42
nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.44
nM
JEG-3 cells
Gestational choriocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.56
nM
MDA-MB-468 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.57
nM
HT29 cells
Colon cancer
Half Maximal Inhibitory Concentration (IC50) 
0.62
nM
NCI-N87 cells
Gastric tubular adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.66
nM
TCCSUP cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.76
nM
HT-1197 cells
Recurrent bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.78
nM
RT-4 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.93
nM
T24 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.95
nM
NCI-H1975 cells
Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.03
nM
HCC1937 cells
Breast ductal carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.05
nM
NCI-H1299 cells
Lung large cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.06
nM
HT-1376 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.34
nM
DMS 114 cells
Lung small cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.53
nM
UM-UC-3 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
4.28
nM
J82 cells
Bladder carcinoma
Half Maximal Inhibitory Concentration (IC50) 
9.01
nM
Hep-G2 cells
Hepatoblastoma
Half Maximal Inhibitory Concentration (IC50) 
9.03
nM
LNCaP cells
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 17 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 28.20% (Day 21) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 0.3 mg/kg single dose.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 54.30% (Day 60) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 0.3 mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Lung cancer CDX model
In Vitro Model Lung cancer Lung cancer cells Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 55.50% (Day 12) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
In Vivo Model Cervical advanced-stage cancer CDX model
In Vitro Model Cervical advanced-stage cancer Cervical advanced-stage cancer cells Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.20% (Day 21) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg single dose.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 96.30% (Day 21) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg single dose.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Negative 5T4 expression (5T4-)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg single dose.

   Click to Show/Hide
In Vivo Model Gastric cancer CDX model
In Vitro Model Gastric cancer Gastric cancer cells Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Negative 5T4 expression (5T4-)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 3.

   Click to Show/Hide
In Vivo Model Gastric cancer CDX model
In Vitro Model Gastric cancer Gastric cancer cells Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 60) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Lung cancer CDX model
In Vitro Model Lung cancer Lung cancer cells Homo sapiens
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 60) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Lung cancer CDX model
In Vitro Model Lung cancer Lung cancer cells Homo sapiens
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 6mg/kg Q4D 4.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 40) Low 5T4 expression (5T4+)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 10 mg/kg single dose.

   Click to Show/Hide
In Vivo Model Cervical cancer CDX model
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 14 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 70) High 5T4 expression (5T4+++)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells (5T4 overexpression) CVCL_0062
Experiment 15 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 70) High 5T4 expression (5T4+++)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells (5T4 overexpression) CVCL_0062
Experiment 16 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 70) High 5T4 expression (5T4+++)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 6mg/kg Q4D 4.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells (5T4 overexpression) CVCL_0062
Experiment 17 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 70) High 5T4 expression (5T4+++)
Method Description
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ubcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 10 mg/kg single dose.
In Vivo Model Breast cancer CDX model
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells (5T4 overexpression) CVCL_0062
Revealed Based on the Cell Line Data
Click To Hide/Show 32 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.07 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.09 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.09 nM High 5T4 expression (5T4+++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder squamous cell carcinoma SCaBER cells CVCL_3599
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.12 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma 5637 cells CVCL_0126
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.12 nM High 5T4 expression (5T4+++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.15 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.17 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Prostate carcinoma DU145 cells CVCL_0105
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.18 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Endocervical adenocarcinoma HeLa cells CVCL_0030
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.23 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.25 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.26 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Skin squamous cell carcinoma A431 cells CVCL_0037
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.31 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma SW780 cells CVCL_1728
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.34 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
Experiment 14 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.42 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Prostate carcinoma PC-3 cells CVCL_0035
Experiment 15 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.42 nM High 5T4 expression (5T4+++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells (5T4 overexpression) CVCL_0062
Experiment 16 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.44 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Gestational choriocarcinoma JEG-3 cells CVCL_0363
Experiment 17 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.56 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 18 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.57 nM Negative 5T4 expression (5T4-)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
Experiment 19 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.62 nM Negative 5T4 expression (5T4-)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 20 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.66 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma TCCSUP cells CVCL_1738
Experiment 21 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.76 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Recurrent bladder carcinoma HT-1197 cells CVCL_1291
Experiment 22 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.78 nM Negative 5T4 expression (5T4-)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma RT-4 cells CVCL_0036
Experiment 23 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.93 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma T24 cells CVCL_0554
Experiment 24 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.95 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Lung adenocarcinoma NCI-H1975 cells CVCL_1511
Experiment 25 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.03 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Breast ductal carcinoma HCC1937 cells CVCL_0290
Experiment 26 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.05 nM Low 5T4 expression (5T4+)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Lung large cell carcinoma NCI-H1299 cells CVCL_0060
Experiment 27 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.06 nM High 5T4 expression (5T4+++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma HT-1376 cells CVCL_1292
Experiment 28 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.34 nM Negative 5T4 expression (5T4-)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Lung small cell carcinoma DMS 114 cells CVCL_1174
Experiment 29 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.53 nM Negative 5T4 expression (5T4-)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma UM-UC-3 cells CVCL_1783
Experiment 30 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 4.28 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Bladder carcinoma J82 cells CVCL_0359
Experiment 31 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 9.01 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Hepatoblastoma Hep-G2 cells CVCL_0027
Experiment 32 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 9.03 nM Moderate 5T4 expression (5T4++)
Method Description
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
References
Ref 1 ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models. Mol Cancer Ther. 2021 Aug;20(8):1327-1337.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.